Electra Therapeutics is advancing a new class of precision therapies designed to eliminate overactive immune cells while sparing normal immune function, aiming to treat life-threatening immune-mediated and oncologic conditions. Its lead candidate, ELA026, is an antibody that targets Signal Regulatory Proteins (SIRP) and is being positioned as the first FDA-approved therapy for secondary hemophagocytic lymphohistiocytosis (sHLH), a hyperinflammatory disease with no approved treatments. Early Phase 1b data showed 100 percent survival at eight weeks in frontline-treated sHLH patients, earning the program FDA Breakthrough Therapy and EMA Priority Medicines designations. The company plans to use newly raised capital to run a global registrational Phase 2/3 study of ELA026 in sHLH and to expand the molecule into hematologic cancers. Proceeds will also fund clinical proof-of-mechanism for a second SIRP-targeting program, ELA822, that has broad potential in immunology and inflammation. Electra’s team, led by President & CEO Kathy Dong, PharmD, MBA, has a track record of translating novel biology into first-in-class therapies. The company’s current financial momentum is driven by a USD 183 million Series C round co-led by EQT Life Sciences and Nextech with participation from strategic and institutional investors.

Total raised

$267M

Funding rounds

2

Latest round

Series C

Latest activity

Oct 2025